Fig. 1
RNAi knockdown of RanBP17 inhibits cell proliferation independent of CDDP treatment. A XTT proliferation assay depicting the relative cell viability of the HNSCC cell line UM-SCC-3 after RNAi knockdown of RanBP17 using pool 1 siRNA (consists of si1, si2, si4, si5 as depicted in D) following incubation with CDDP (6.25, 12.5, 25, 50 and 100 µmol/L). Note the significant reduction in cell viability at 0 µmol/L CDDP in UM-SCC-3 cells after RanBP17 knockdown. B Effect of RanBP17 RNAi knockdown alone (using pool 1 siRNA) was tested in the indicated cell lines. Efficient RNAi knockdown of RanBP17 RNA using pool 1 siRNA is shown for HCT116p53 wt/wt cells. C The 3 most responsive cell lines from B were used to evaluate the effect of all 8 single RanBP17 specific siRNAs (si1-8). D Depicted are the siRNA (si1-8) binding sites as well as their location within the RanBP17 reference sequence NM_022897.4. Also included is the respective information for the updated RanBP17 reference sequence NM_022897.5, which differs from NM_022897.4 by lacking the first 136 nucleotides. Underlined nucleotides refer to the nucleotide sequence of the adjacent exon (shown in brackets). NT_non target RNA, siRanBP17=silencing RNA (pool 1) directed against RanBP17. Statistical tests; A, B, C: Unpaired Students t-test, two-sided (n=4 for all analyses) *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001